

PRESS RELEASE

Metropolis Healthcare reports Normalised PAT Growth of 26% for Full Year FY2024-25 and 24% in Q4FY25

~ Achieves Double-Digit Revenue Growth at 12% YoY for FY 2024-25 and 10% YoY in Q4FY25, driven by Consistent Volume Expansion~
~ TruHealth and Specialty Lead as Fastest-Growing Segments ~

Mumbai, India, 13th May, 2025: Ameera Shah-led Metropolis Healthcare Limited (**NSE: METROPOLIS | BSE: 542650**), India's second-largest and most respected pathology laboratory chain, today announced its audited consolidated financial results for the quarter ended March 31st, 2025

FY25 and Q4FY25 Key Financial Highlights

- **Metropolis records revenue of INR 1,331 Crore in FY25 and INR 345 Crore in Q4FY25.**
- **Patient volume grew by 6% YoY and Test Volume grew by 7%, in FY25.** Revenue per Patient saw a robust 6% YoY growth, enabled by scientific upselling and benefits from micro-market pricing.
- **B2C revenues saw a robust 17% YoY growth in FY25 and 14% YoY in Q4FY25,** fueled by the company's ongoing investment in consumer experience and the expansion of service network.
- **B2B revenue grew 12% YoY in FY25 and 10% YoY in Q4FY25,** on account of enhanced B2B service quality and partner engagement programs.
- In FY25, **TruHealth revenue grew 24% YoY with a strong Q4 exit contributing 19% to total revenue.**
- **Specialty diagnostics** also maintained momentum, **growing 13% YoY in FY25**
- **Revenue growth contribution from Tier III cities stood at 18% in FY25.**
- **Expanded to 750+ towns in FY25 with addition of 29 new labs and 400 centres in FY25, enhancing last-mile access.**

"Over the past four years, Metropolis has built a resilient, future-ready organization through strategic investments in laboratories, network expansion, brand, technology, and talent. Despite a challenging environment, we have strengthened our scientific leadership, enhanced customer engagement, and driving operational excellence.

We are confident that our recent acquisitions — Core Diagnostics, Scientific Pathology, and Dr. Ahuja's Pathology & Imaging Centre — will generate strong returns and fuel the next phase of growth. These acquisitions reinforce our leadership in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India. With a robust foundation, a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value." ~ **Ameera Shah, Executive Chairperson & Whole-time Director, Metropolis Healthcare Limited.**

"FY25 has been a pivotal year in our journey toward becoming a more consumer-centric and digitally enabled diagnostics brand. Our growth was fuelled by rising demand for preventive and specialized testing, enabled by focused execution, stronger clinician engagement, and meaningful innovation. We introduced industry-first cancer screening panels and tools, along with AI-powered diagnostics to enhance accuracy and enable early detection. Our proprietary engine, MetAdvisor, uses historical data to deliver personalized, science-led test recommendations—boosting TruHealth performance.

As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care. With science at the heart of our efforts, we aim to make quality diagnostics more accessible, reliable, and impactful for the communities we serve.” ~ **Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare Limited.**

Financial Results Snapshot:

In INR Crs.	FY25	FY24	Y-o-Y	Q4FY25	Q4FY24	Y-o-Y
Revenue from Operations	1,331	1,189	12%	345	313	10%
Adj. EBITDA*	325	285	14%	84	80	5%
Adj. EBITDA* (%)	24.4%	23.9%		24.3%	25.5%	
Profit After Tax	146	128	14%	29	36	-19%
PAT Margin (%)	10.9%	10.8%		8.5%	11.6%	
Normalized PAT	161	128	26%	45	36	24%
Normalized PAT Margin (%)	12.1%	10.8%		13.0%	11.6%	

*EBIDTA adjusted for one off expenses related to 3 acquisitions, Costs linked to legal & professional fees for tax cases & small provision for Inventory

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 22 states, 3 Union Territories, and over 750+ towns in India, supported by a robust network of more than 210 laboratories, 4,500 patient service centers, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes. Metropolis offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 98% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

Safe harbor statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd. CIN -L73100MH2000PLC192798 Mr. Jeyasingh Balakrishnan Head - Corporate Communications jeyasingh.b@metropolisindia.com	Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff +91 77383 77756 / +91 98205 19303 shogun.jain@sgapl.net / sagar.shroff@sgapl.net
---	---